Leukemia - Acute
B lymphoblastic leukemia / lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)
Reviewer: Daniela Mihova, M.D. (see Reviewers page)
Revised: 2 February 17 January 2013, last major update September 2012
Copyright: (c) 2001-2013, PathologyOutlines.com, Inc.
● 20-30% of childhood preB ALL; most common translocation (Chin Med J (Engl) 2003;116:1298, Atlas of Genetics and Cytogenetics in Oncology and Haematology), but not infants; also 3% of adults
● 5 different patterns of gene expression involving 14 genes, can detect with gene chip (BMC Genomics 2007;8:385)
● Excellent prognosis due to good response to chemotherapy; 90% remissions; relapses occur later than other ALL
● Persistence of TEL-AML1 transcripts is not necessarily related to relapse (Pediatr Int 2003;45:275)
● No distinct morphology
● CD10 (bright), CD19, CD34, HLA-DR
● Also CD13 and CD33 (Diagn Mol Pathol 2000;9:184)
● CD9, CD20
● Fusion of TEL/ETV6 and AML1/RUNX1/CBFA2 genes
● Detect with FISH or PCR; not found by conventional cytogenetics (i.e. are cryptic) because rearranged segments are too small;
● May have no other molecular abnormalities, almost never > 50 chromosomes
End of Leukemia - Acute > PreB ALL > B lymphoblastic leukemia / lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).